Journal of Psychopharmacology

Article	Citations
Science, safety and education: Informing the psychedelic treatment of psychiatric disorders	218
The effects of the PDE4 inhibitor roflumilast on cognitive performance after a cerebrovascular accident: a double-blind randomized placebo-controlled trial with an open label extension (ROSTMEMA)	144
Cannabimimetic and discriminative stimulus effects of hexahydrocannabinols in mice	133
Circadian rhythmicity in prepulse inhibition of the acoustic startle response: A study of chronotype and time-of-day effects in young healthy adults	103
Effects of initial nicotine exposure on cognition and nicotine reinforcement among non-smoking young adults with and without attention deficit hyperactivity disorder	74
Award winning abstracts presented at the 15 th Annual International College of Mental Health Pharmacy (CMHP) Conference, Liverpool, UK, on 10	60
Deaths related to the use of diarylethylamines, with a focus on the United Kingdom: A systematic review and case series report	59
Off the RADAR; questions regarding the trial protocol of a randomised controlled trial of antipsychotic reduction and discontinuation	58
Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study	56
Effectiveness of vortioxetine in elderly patients with major depressive disorder in real-world clinical practice: Results from the RELIEVE study	54
Proportion of Antipsychotics with CYP2D6 Pharmacogenetic (PGx) Associations Prescribed in an Early Intervention in Psychosis (EIP) Cohort: A Cross-Sectional Study	53
Meditating on psychedelics. A randomized placebo-controlled study of DMT and harmine in a mindfulness retreat	53
Neurocognitive changes in lithium-treated older adult bipolar patients on antipsychotics	53
Psychedelics and the ‘inner healer’: Myth or mechanism?	52
Co-use of psychedelics with other substances: Findings from the global psychedelic survey	51
Preliminary evidence that serum interleukin-6 is a candidate biomarker of response to esketamine in treatment-resistant depression	50
The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies	47
Solriamfetol improves daily fatigue symptoms in adults with myalgic encephalomyelitis/chronic fatigue syndrome after 8 weeks of treatment	47
Relationship between change in social evaluation learning and mood in early antidepressant treatment: A prospective cohort study in primary care	42
An α7 nAChR approach for the baseline-dependent modulation of deviance detection in schizophrenia: A pilot study assessing the combined effect of CDP-choline and galantamine	42
The effects of antenatal depression and SSRI exposure on children: A systematic review	40
A framework for assessment of adverse events occurring in psychedelic-assisted therapies	39
Dynamic excitatory-inhibitory differences in autistic and non-autistic adults: Evidence from a pharmacological challenge with arbaclofen	39
Psychedelic research – Going global	37
A reflection on paradigmatic tensions within the FDA advisory committee for MDMA-assisted therapy	37

Comparison of average time-to-relapse following ECT versus ketamine – A systematic review	36
Cannabidiol in clinical and preclinical anxiety research. A systematic review into concentration–effect relations using the IB-de-risk tool	33
Associations between regular cannabis use and brain resting-state functional connectivity in adolescents and adults	33
The D1/D2-like receptor antagonist flupentixol and the D2-like receptor antagonist L-741626 decrease operant responding for nicotine and food and locomotor activity in male and female rats	33
Ketamine use in a large global sample: Characteristics, patterns of use and emergency medical treatment	32
Pharmaco-fUS in cognitive impairment: Lessons from a preclinical model	32
Mind the gap! Addressing unresolved aspects of abuse potential evaluation and scheduling of classic and novel psychedelic drugs	31
Serotonin release by parachloroamphetamine in rats with high and low sociability: High prefrontal release capacity in sociable females	31
Voluntary nicotine consumption and reward in a subset of diversity outbred founder strains	31
Corrigendum: Is psychedelic use associated with cancer? Interrogating a half-century-old claim using contemporary population-level data	30
Not too quick on “Debunking the myth of ‘Blue Mondays’”	30
The empathogen 3,4-methylenedioxymethamphetamine, but not methamphetamine, increases feelings of global trust	28
Every prescription is a prediction	28
What are set and setting: Reducing vagueness to improve research and clinical practice	28
The therapeutic readiness of probiotics in major depressive disorder: A systematic review of randomised controlled trials	27
The 5-HT1A receptor biased agonists, NLX-204 and NLX-101, like ketamine, elicit rapid-acting antidepressant activity in the rat chronic mild stress model via cortical mechanisms	27
Haloperidol dopamine receptor occupancy and antagonism correspond to delirium agitation scores and EPS risk: A PBPK-PD modeling analysis	26
The renin angiotensin system in cognitive flexibility: Effects of single-dose losartan on task-switching in healthy volunteers	26
Ten practical suggestions for setting up a psychedelic study	25
The New Zealand drug harms ranking study: A multi-criteria decision analysis	24
Effects of LSD, DMT and psilocybin on cognitive and psychological functions: A systematic review of the literature	23
A phase 1b study to investigate the potential interactions between ASP8062 and buprenorphine/naloxone in patients with opioid use disorder	23
The goal of specificity in psychotropic drug development: A lesson from Sisyphus?	23
Associations of antidepressants and antipsychotics with lipid parameters: Do CYP2C19 / CYP2D6 genes play a	23
The low risk for early renal damage during lithium treatment has not changed over time	21
Antipsychotic co-medication and treatment response to rTMS and iTBS in depression: Data from clinical records from two independent clinical sites	21
Psychedelic-assisted psychotherapy: The need to monitor adverse events	21
Cardiovascular mortality and depression: A systematic review and meta-analysis of the association with antidepressant treatment and co-morbidity	21
Wistar Kyoto rats exhibit decreased serotonin neuronal firing and increased norepinephrine burst activity but dampened hippocampal α 2 -adrenoceptor	21
Impact of psychedelics on craving in addiction: A systematic review	20
Silence is golden: Documenting the speech production of participants and support providers in psilocybin administration sessions for the treatment of post-traumatic stress disorder	20
The mechanism of action of clozapine	20
Statistical limitations of the claimed dose–response in “Dose–response efficacy and safety of lumateperone in bipolar depression: A preliminary meta-analysis of randomized controlled trials”	20
A randomised double-blind, placebo-controlled trial of pramipexole in addition to mood stabilisers for patients with treatment-resistant bipolar depression (the PAX-BD study)	19
Ketamine/esketamine pharmacotherapy for treatment of anxiety disorders and anxiety symptoms in depression: Systematic review	19
The helioscope effect: A new framework for evaluating trauma-related memory processing in psychedelic experiences	19
Oxytocin prevents ketamine-induced executive control deficits in macaque monkeys	19
Genetic background and sex moderate the effects of adolescent nicotine exposure on adult functional neural circuits and behavior	18
Pharmacokinetics and pharmacodynamics of orally administered S-ketamine in healthy participants	18
Drug–drug interactions involving classic psychedelics: A systematic review	18
Oral esketamine for patients with severe treatment-resistant depression: Effectiveness, safety, and tolerability of a six-week open-label treatment program	18
Association of clozapine treatment and rate of methamphetamine or amphetamine relapses and abstinence among individuals with concurrent schizophrenia spectrum and amphetamine use disorder: A retrospec	17
Associations between MDMA/ecstasy use and physical health in a U.S. population-based survey sample	17
Evaluation of the sedative-motor effects of novel GABAkine imidazodiazepines using quantitative observation techniques in rhesus monkeys	17
Hippocampal phase precession is preserved under ketamine, but the range of precession across a theta cycle is reduced	17
Evidence-based guidelines for the interpretation of the 9-item Concise Health Risk Tracking – Self-Report (CHRT-SR 9 ) measure of suicidal risk	17
Effect of CannEpil ® on simulated driving performance and co-monitoring of ocular activity: A randomised controlled trial	17
Psilocybin for clinical indications: A scoping review	16
Validation of ratings on the six-item Positive and Negative Syndrome Scale obtained via the Simplified Negative and Positive Symptoms Interview among outpatients with schizophrenia	16
Associations between paraoxonase-1 activity and therapeutic drug monitoring indicators in schizophrenia patients treated with olanzapine: A cross-sectional study	16

Eight-week antidepressant treatment effects on connectome gradient in first-episode drug-naïve patients with major depressive disorder	16
The intersection between psychedelics and schizophrenia spectrum disorders: Reevaluating risk and therapeutic potential	15
Factor analysis of treatment acceptability in double-blind randomised clinical trial of home-based transcranial direct current stimulation in major depression and in healthy individuals	15
The effects of reserpine on depression: A systematic review	15
Examining mystical experiences as a predictor of psilocybin-assisted psychotherapy for treatment-resistant depression	15
A critical evaluation of QIDS-SR-16 using data from a trial of psilocybin therapy versus escitalopram treatment for depression	15
A three-stage strategy for conducting an experimental investigation: A recommendation to improve the reproducibility of reported conclusions	14
Negative affect interacts with perceptual affective biases	14
Assessment of the reporting of harms in systematic reviews focused on hallucinogens: A cross-sectional study	14
The impact of antidepressant use on MDMA fatalities: A matched case-control study using a post-mortem database	14
The increasing use of cognitive enhancing drugs by those with ADHD and neurotypical individuals: Societal demands, lifestyle preferences, and ethical issues	14
Chronic Cannabis users exhibit altered oscillatory dynamics and functional connectivity serving visuospatial processing	14
Can psychedelics enhance group psychotherapy? A discussion on the therapeutic factors	14
Escitalopram and functional connectivity in major depressive disorder: A systematic review	14
Blackcurrant ( Ribes nigrum L.) improves cholinergic signaling and protects against chronic Scopolamine-induced memory impairment in mice	13
Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research	13
Modafinil: A closer look at its theoretical toxicological potential	13
Pivotal role of orexin signaling in the posterior paraventricular nucleus of the thalamus during the stress-induced reinstatement of oxycodone-seeking behavior	13
Is lack of goal-conflict-specific rhythmicity a biomarker for treatment resistance in generalised anxiety but not social anxiety or major depression?	13
Exploring the efficacy and safety of a novel standardized ashwagandha ( Withania somnifera ) root extract (Witholytin®) in adults experiencing high stres	13
Evaluating the abuse liability of ketamine in the treatment of mood disorders: A systematic review	12
Mechanisms of psilocybin on the treatment of posttraumatic stress disorder	12
Older adults in psychedelic-assisted therapy trials: A systematic review	12
Episodic foresight is impaired following acute alcohol intoxication	12
Effects of cannabidiol on behavioral and psychological symptoms of vascular dementia: A randomized, double-blind, placebo-controlled clinical trial	12
Revisiting monoamine oxidase inhibitors: A potential dual-action therapy for patients with prostate cancer and comorbid depression?	12
Efficacy and safety of pharmacological and non-pharmacological interventions for antipsychotic-induced weight gain in individuals with schizophrenia: A systematic review and network meta-analysis of 5	12
Subjectively reported sleep improvement with antipsychotic medications in clinical practice: A systematic review, meta-analysis and meta-regression of moderating factors	12
Amphetamine use disorder is associated with striatum hypoactivation during anticipation of loss and reward	12
Risk of major congenital malformations and heart defects in pregnancies exposed to first-trimester drugs for depression and co-medications	12
Predictors of therapeutic response to psychedelic-assisted therapy: A systematic review	12
We need to talk: The urgent conversation on chronic pain, mental health, prescribing patterns and the opioid crisis	12
Just a gut feeling: Faecal microbiota transplant for treatment of depression – A mini-review	12
Effects of psilocybin on personality, psychiatric symptoms, and values: Exploring mediating effects of the acute psychedelic experience	11
Long-term neurocognitive side effects of MDMA in recreational ecstasy users following sustained abstinence: A systematic review and meta-analysis	11
Younger, drunk, and fast: Paradoxical rapid reaction time in hazardous drinkers	11
The association between N -methyl- d -aspartate receptor availability and glutamate levels: A multi-mo	11
A randomized, double-blind, placebo-controlled, Phase 1 study to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of an immediate-release oral ketamine capsule in healthy vo	11
A systematic review of the pharmacokinetics of classical serotonergic psychedelic compounds in healthy adult subjects	11
The psychedelic effects of cannabis: A review of the literature	11
Common protein networks for various drug regimens of major depression are associated with complement and immunity	11
Temporal profile of intranasal oxytocin in the human autonomic nervous system at rest: An electrocardiography and pupillometry study	11
The role of psychopharmacology and cognitive neuroscience in understanding the brain in the treatment of psychiatric disorders and neurological diseases for the benefit of society	11
Beyond symptom reduction: DMT improves anxiety, life satisfaction, and quality of life in healthy volunteers and patients with depression	11
No evidence for deleterious effects of psilocybin and MDMA on working memory or related neurophysiological activity in a non-clinical population: An uncontrolled exploratory study	11
Recasting the role of electroconvulsive therapy and the electroconvulsive therapy practitioner: For severe illness, not necessarily treatment-resistant depression	11
Intracerebroventricular knockdown of NPY1R disrupts NPY1R-GALR2/TrkB heteroreceptor complexes without affecting neuroplasticity or depressive-like behaviour	11
Real-world effectiveness of repeated intravenous ketamine infusions for treatment-resistant depression in transitional age youth	10
OAV and 5D-ASC for Brazilian Portuguese: A validation and adaptation study	10
Predicting and exploring ayahuasca effects: Perception, mind-wandering, and EEG oscillations	10
Concomitant use of antidepressants and classic psychedelics: A scoping review	10
Tripping into the unknown: Exploring the experiences of first-time LSD users through global drug survey insights	10
Pictorial representation of illness and self measure (PRISM): A putative transdiagnostic tool for evaluating therapeutic effects of psychedelic treatments	10
Sub-anesthetic doses of ketamine increase single cell entrainment in the rat auditory cortex during auditory steady-state response	10
No evidence that post-training dopamine D2 receptor agonism affects fear generalization in male rats	9
The interaction between kynurenine pathway, suicidal ideation and augmentation therapy with minocycline in patients with treatment-resistant depression	9
Causes, clinical characteristics, and outcomes of high lithium levels and intoxications: Retrospective analysis of patient records	9
A transdiagnostic systematic review and meta-analysis of ketamine’s anxiolytic effects	9
Role of chemokines in depression: Highlights on CX 3 CL1/CX 3 CR1 signaling	9
Unveiling potential adverse events associated with escitalopram oxalate: A real-world analysis based FDA adverse event reporting system database	9
Changes in music-evoked emotion and ventral striatal functional connectivity after psilocybin therapy for depression	9
Is there a risk of addiction to ketamine during the treatment of depression? A systematic review of available literature	8
Landscape analysis of pre-registered clinical trials involving classical psychedelics	8
Prenatal THC exposure and binge-like alcohol drinking in early adolescence: From sex-specific drinking vulnerability to abnormal endocannabinoid-dopamine nexus in the nucleus accumbens	8
Escitalopram should be investigated in anorexia nervosa: Rationale and review of mechanisms	8
Role of serotonin in modulation of decision-making in Parkinson’s disease	8
Clinical correlates of early onset antipsychotic treatment resistance	8
Ketamine: A new chapter for clinical psychopharmacology?	8
Self-treatment of psychiatric conditions using ketamine: Patterns, characteristics, and retrospective insights	8
Common pitfalls, and how to avoid them, in child and adolescent psychopharmacology: Part I	8
Effects of clozapine treatment on the improvement of substance use disorders other than nicotine in individuals with schizophrenia spectrum disorders: A systematic review and meta-analysis	8
Investigation of self-treatment with lysergic acid diethylamide and psilocybin mushrooms: Findings from the Global Drug Survey 2020	8
Interactions of alcohol and the benzodiazepine inverse agonist in healthy male volunteers	8
Targeting disrupted networks in schizophrenia: Can muscarinic drugs make a fundamental difference?	8
Mediators of treatment response in a clinical trial of naltrexone and bupropion for methamphetamine use disorder: A longitudinal mediation analysis	8
Hemispheric annealing and lateralization under psychedelics (HEALS): A novel hypothesis of psychedelic action in the brain	8
Trip killers: Addressing a critical knowledge gap in psychedelic research	8
Hippocampal and parahippocampal volume and function predict antidepressant response in patients with major depression: A multimodal neuroimaging study	8
Appraisal of the validity of preclinical investigations to predict the efficacy of psychedelic drugs as fast-acting antidepressants	7
Acute behavioural effects of low-dose cannabidiol: A randomised crossover trial in healthy volunteers	7

From monotherapy to sequential models: An updated scoping review on ibogaine’s role in treatment for psychiatric disorders	7
Role of α1-GABA A receptors in the serotonergic dorsal raphe nucleus in models of opioid reward, anxiety, and depression	7
Development of the Protective Strategies for Psychedelics Scale: A novel inventory to assess safety strategies in the context of psychedelics	7
Set and setting of psychedelics for therapeutic use in psychiatry: A systematic review	7
Psilocybin history, action and reaction: A narrative clinical review	7
Roland R. Griffiths, psychopharmacology pioneer: Abuse liability, alcohol, nicotine, caffeine, benzodiazepines, and psychedelics	7
Monoamine neurotransmitter-related gene-based genome-wide association study of low-dose ketamine in patients with treatment-resistant depression	7
Exploring the impact of MDMA and oxytocin ligands on anxiety and social responses: A comprehensive behavioural and molecular study in the zebrafish model	7
“Too small to succeed?” Rethinking efficacy claims in a solriamfetol trial for ME/CFS	7
Effect of ashwagandha ( Withania somnifera ) extract with Sominone (Somin-On™) to improve memory in adults with mild cognitive impairment: A randomized,	7
The efficacy of vortioxetine in the acute treatment of major depressive disorder: A systematic review and meta-analysis	7
Modification of natural tryptamines for the treatment of neuropsychiatric diseases	7
Angiotensin II and angiotensin-(1–7) neurotransmissions in the medial amygdala differently control cardiovascular and anxiogenic-like responses to stress in rats	7
An exploration of the relationships between the effects of psilocybin on behavior, 5-HT 2A receptor occupancy, and neuroplastic effects in mice	7
Mapping acute alcohol effects on bodily sensations: A cross-dimensional interoceptive approach	7
Co-medication with disulfiram markedly increased serum clozapine levels: Two case reports	7
Main targets of ibogaine and noribogaine associated with its putative anti-addictive effects: A mechanistic overview	7
Naturalistic use of psychedelics is associated with longitudinal improvements in anxiety and depression during global crisis times	7
Roles of the 5-HT1A receptor in zebrafish responses to potential threat and in sociality	6
Commentary on Cochrane review: “Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder”	6
β -blockers’ neuropsychiatric risks: Overlooked evidence?	6
Influence of GABA A and GABA B receptor activation on auditory sensory gating and its association	6
Harnessing placebo: Lessons from psychedelic science	6
Psilocybin reduces fear memory and restores neuroplasticity in the hippocampus and medial prefrontal cortex	6
Higher orexin-A levels are associated with treatment response to clozapine in patients with schizophrenia: A cross-sectional study	6
A systematic review and narrative summary of the therapeutic potential of classic serotonergic psychedelics for smoking cessation and reduction	6
Award winning abstracts presented at the 14 th Annual International College of Mental Health Pharmacy (CMHP) Conference Glasgow, UK, on 11	6
Fluoxetine rescues the depressive-like behaviour induced by reserpine and the altered emotional behaviour induced by nicotine withdrawal in zebrafish: Involvement of tyrosine hydroxylase	6
Nucleus accumbens serotonin 1A receptor expression is altered by female reproduction and regulates postpartum affective and caregiving behaviors	6
Metformin efficacy and safety as an adjunctive treatment for irritability in children with autism spectrum disorder: A randomized, double-blind, placebo-controlled trial	6
Impact of patient-specific factors on clozapine metabolism in individuals with treatment-resistant schizophrenia or schizoaffective disorder	6
Severe neutropenia unrelated to clozapine in patients receiving clozapine	6
Characteristics of poisonings involving ketamine in the United States, 2019–2021	6
Efficacy and adverse effect profile of vortioxetine in major depressive disorder: A meta-analysis	6
Comparative efficacy of quetiapine by dose and formulation for psychosis in schizophrenia: A systematic review and dose–response model-based network meta-analysis	6
Influence of panic disorder and paroxetine on brain functional hubs in drug-free patients	6
Effects of antidepressants, anesthetics and sedatives/hypnotics on sleep-associated memory consolidation – A systematic review	6
Exploring clozapine use in severe psychiatric symptoms associated with autism spectrum disorder: A scoping review	5
Impaired face symmetry detection under alcohol, but no ‘beer goggles’ effect	5
Pharmacokinetics and pharmacodynamics of sublingual microdosed lysergic acid diethylamide in healthy adult volunteers	5
Effects of gamma-aminobutyric acid on working memory and attention: A randomized, double-blinded, placebo-controlled, crossover trial	5
MDMA enhances positive affective responses to social feedback	5
Associations of treatment with hypnotics with suicide and attempted suicide: A nationwide cohort study	5
Catalyst for change: Psilocybin’s antidepressant mechanisms—A systematic review	5
Mechanistic insights into the safety of daridorexant in older adults: From postural stability to next-day function	5
Boosting the ventrolateral periaqueductal gray-ventral tegmental area pathway by disinhibition of group II mGluRs alleviates chronic restraint stress-induced depression-like behavior in mice	5
Mitochondrial dysfunction in schizophrenia and its modulation by atypical antipsychotic drugs: A randomized controlled trial	5
Abuse potential assessment of the dual orexin receptor antagonist daridorexant in rats	5
Fluoroquinolones and risk of nightmares: A literature review and disproportionality analysis using individual case safety reports from Food and Drug Administration Adverse Event Reporting System datab	5
Antipsychotic action and symptom specificity – down the bioinformatic rabbit hole	5
Cell-based serum anticholinergic activity assay and working memory in cognitively healthy older adults before and after scopolamine: An exploratory study	5
Six weeks open-label oral ketamine for patients with treatment-resistant depression, post-traumatic stress disorder, or obsessive-compulsive disorder	5
Reduced attentional lapses in male rats following a combination treatment of low-dose D-serine and atomoxetine	5
Long-read sequencing of CYP2D6 may improve psychotropic prescribing and treatment outcomes: A systematic review and meta-analysis	5
Unequal representation? A cross-sectional analysis of age, sex, race, and ethnicity in clinical trials of classic psychedelics	5
Associations between psychedelic use and migraine history in Swedish twins	5
Adolescent substance use trajectories are associated with nucleus accumbens functional connectivity	5
Speech markers of psychological change following a psychedelic 5-MeO-DMT retreat	5
The risk of chronic psychedelic and MDMA microdosing for valvular heart disease	5
Naturalistic psychedelic therapy: The role of relaxation and subjective drug effects in antidepressant response	5
Single-dose psilocybin therapy for alcohol use disorder: Pharmacokinetics, feasibility, safety and efficacy in an open-label study	5
Habitual caffeine intake, genetics and cognitive performance	5
Individual differences in cocaine-induced conditioned place preference in male rats: Behavioral and transcriptomic evidence	5
The pseudoscience of lithium and suicide: Reanalysis of a misleading meta-analysis	5
Antipsychotic polypharmacy and high-dose antipsychotic therapy compared to antipsychotic monotherapy at standard doses in schizophrenia – a systematic review	5
Challenges with clinical trial participants in studies with classical psychedelics: A position statement from the National Network of Depression Centers’ task group on psychedelics and related compoun	5
Clozapine rechallenge or continuation despite neutropenia or agranulocytosis using colony-stimulating factor: A systematic review	5
The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients	4
Dose of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding in older adults	4
Psychiatric risks for worsened mental health after psychedelic use	4
Compassionate use of esketamine intranasal in patients with severe major depressive disorder resistant to the treatment	4
Repeated administration of L-alanine to mice reduces behavioural despair and increases hippocampal mammalian target of rapamycin signalling: Analysis of gender and metabolic effects	4
Ketamine for refractory depression: Save the best for last?	4
Clinical effects of CYP2D6 phenoconversion in patients with psychosis	4
Can cannabinoids alleviate behavioral symptoms in older adults with dementia? A systematic review	4
Less is more? A review of psilocybin microdosing	4
Prenatal cannabis use is associated with altered miRNA and protein expression in the developing human brain	4
Predicting clozapine dose required to achieve a therapeutic plasma concentration – A comparison of a population algorithm and three algorithms based on gene variant models	4
The Afterglow Inventory (AGI): Validation of a new instrument for measuring subacute effects of classic serotonergic psychedelics	4
Risk of bias in randomized clinical trials on psychedelic medicine: A systematic review	4
Antidepressant initiation and the risk of treatment-emergent mania in children and adolescents with depression: A real-world cohort study	4
A phase 1 randomized, placebo-controlled study to investigate potential interactions between ASP8062, a positive allosteric modulator of the GABA B r	4
Award winning abstracts presented at the 12th Annual International College of Mental Health Pharmacy (CMHP) Conference, Northampton, UK on 7th and 8th October 2022	4
Effects of pimavanserin, xanomeline and highly-purified plant-derived cannabidiol on MK-801-induced behaviours in mice relevant to psychosis	4
Common pitfalls, and how to avoid them, in child and adolescent psychopharmacology: Part II	4
Should we be leery of being Leary? Concerns about psychedelic use by psychedelic researchers	4
Reward-related neural activity after low doses of LSD in participants with depressed mood	4
Ketamine-induced changes in resting state connectivity, 2 h after the drug administration in patients with remitted depression	4
The impact of cannabidiol placebo on amygdala-based neural responses to an acute stressor	4
Esketamine nasal spray for treatment-resistant depression: A retrospective multicenter real-world cohort study on effectiveness and suicidal outcomes	4
Low-frequency monitoring for community clozapine initiations: A comparative study relative to standard frequency assessments	4
Peri-traumatic consumption of classic psychedelics is associated with lower anxiety and post-traumatic responses 3 weeks after exposure	4
Confronting mortality: A meta-analysis and systematic review of psychedelic experiences and death anxiety	4
Rapid and sustained reduction of treatment-resistant PTSD symptoms after intravenous ketamine in a real-world, psychedelic paradigm	4
Cognition-enhancing effect of YL-IPA08, a potent ligand for the translocator protein (18 kDa) in the 5 × FAD transgenic mouse model of Alzheimer’s pathology	4